ClinicalTrials.gg
RecruitingNCT07677319SAGE-HeartUpdated Jun 30, 2026

SAGE-Heart : Senior Assessment fraGility and Post-opErative QALYs 1 Year After Emergency HEART Surgery for Patients Aged 75 and Older

An interventional study of Phone Calls in Frailty, Cardiac Surgery and QALYs, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Dec 2025, registered Jun 2026).
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
265
Allocation
Non-randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 59 studies in Frailty with a site in France — 23 open to participants now, 25 under way, none of them phase 3. Frailty · France.

Planned enrollment
8th of 27
265 · median 106
Started
2025
with 9 others
No phase
27 of 59
9 open now
Primary completion
2028-12
later than 19 of 24 live
Registered
56th of 59
by date
Lead sponsor
2 of 59
University Hospital, Bordeaux

Among the 59 studies in Frailty with a site in France, this one is the 8th largest by planned enrollment of the 27 interventional ones that give a count, is one of 10 that started in 2025, is one of 27 with no phase, reaches primary completion later than 19 of the 24 other live ones, and was the 56th registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

23 of the 59 studies in Frailty with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Frailty with a site in France, or all of them as a file.
02

Study summary

The hypothesis is that the preoperative Clinical Frailty Score (CFS) is a predictive factor for a loss in quality-adjusted life years (QALYs) one year after emergency cardiac surgery under cardiopulmonary bypass (CPB) in patients aged 75 years and older.

Read the detailed description

The advancement of structural cardiology, particularly with percutaneous valve interventions, offers new treatment options without the need for cardiopulmonary bypass (CPB). Despite an increase in the use of these techniques, some studies highlight a notable rise in CPB usage in patients aged 80 and over, from 13.8% in 2013 to 20.5% in 2022. In France, the population aged 85 and above is expected to triple by 2050, meaning more elderly patients will be eligible for CPB cardiac surgery. Several global studies have examined the outcomes of older individuals undergoing CPB cardiac surgery. While EuroSCORE II and STS scores are effective in predicting short-term mortality, they lack accuracy in predicting long-term mortality, particularly in frail patients, and do not assess quality of life. New tools to evaluate frailty, such as the Clinical Frailty Scale (CFS), are now used in preoperative assessments for planned cardiac interventions. Identifying frail elderly patients early is crucial for improving patient and family information on care plans, especially in high-risk surgeries. Even in emergencies, patients must remain involved in their health decisions, and multidisciplinary collaboration is vital for improving postoperative recovery and quality of life.

Data will be collected :

  • Preoperative: During the anesthesia consultation: Calculation of the CFS (frailty assessment = CFS ≥ 4) EuroQoL 5D-5L (quality of life, with the index calculated with the French value set of the EuroQol), and routine care (renal function: urea, creatinine, albumin levels).
  • Postoperative (ICU and hospital): Collection of complication incidence, mortality (all causes and LATA-related).
  • Follow-up (by phone at 3, 6, and 12 months): CFS and EuroQoL scores, prevalence of chronic pain and analgesic use, dialysis dependency, accommodation status, readmission rates, and death date if applicable.
03

Conditions studied

  • Frailty
  • Cardiac Surgery
  • QALYs

Browse trials for

Keywords

  • Frailty
  • Elderly
  • Cardiac Surgery
  • Cardio-pulmonary Bypass
  • QALYs
  • Clinical Frailty Scale
  • EuroQol, postoperative
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ≥ 75 years who are affiliated with or beneficiaries of a social security scheme and undergoing emergency cardiac surgery under cardiopulmonary bypass, either immediate or urgent (relative) :

    • Immediate emergency surgery: intervention performed before the start of the next working day following the decision to operate,
    • Urgent (relative) emergency surgery: patients not admitted electively for surgery but requiring an intervention during the current hospital stay for medical reasons, and who cannot be discharged without undergoing a definitive procedure

Exclusion criteria

Exclusion Criteria:

  • Patients requiring preoperative cardiopulmonary resuscitation
  • Scheduled (elective) surgery
  • Lack of
  • Impaired consciousness at the time of inclusion (defined by a Glasgow Coma Scale score \< 15)
  • Individuals under legal guardianship or judicial protection
  • Individuals participating in another interventional research protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
265 participants (estimated)

Study arms

  • Experimental
    Frail group

    Patients with Clinical Frailty Score CFS ≥ 4

    Other: Phone Calls

  • Experimental
    Non-frail group

    Patients with Clinical Frailty Score CFS \< 4

    Other: Phone Calls

Interventions

  • OtherPhone Calls

    Phone calls will be made at 3, 6, and 12 months to report quality of life scores (EuroQol EQ 5D-5L) and other postoperative data

06

What researchers measure

Primary outcomes

  1. Quality-Adjusted Life Years (QALYs) according to preoperative frailty status

    QALYs over the 12-month follow-up will be estimated from EQ-5D-5L utility scores collected at baseline, Month 3, Month 6, and Month 12 together with survival data, and compared between participants with preoperative frailty (Clinical Frailty Scale ≥4) and those without frailty (Clinical Frailty Scale \<4), with adjustment for EuroSCORE II.

    Time frame: Month 12

Secondary outcomes

  1. Postoperative complications

    Incidence of postoperative cardiac, respiratory, renal, infectious, and neurological complications during the first 28 postoperative days.

    Time frame: From surgery through,Day 28

  2. All-cause mortality

    All-cause mortality assessed during ICU stay, hospital stay, and at Month 3, Month 6, and Month 12.

    Time frame: Through Month 12

  3. EQ-5D-5L Utility Index

    Health-related quality of life assessed using the EQ-5D-5L utility index derived from the French value set

    Time frame: Baseline, Month 3, Month 6, and Month 12

  4. Dialysis dependence

    Dialysis dependence among participants not receiving chronic dialysis before surgery.

    Time frame: Month 3, Month 6, and Month 12

  5. Length of intensive care unit stay

    Duration of postoperative ICU stay.

    Time frame: From ICU admission to ICU discharge (assessed up to Day 28)

  6. Length of hospital stay

    Total postoperative hospital length of stay.

    Time frame: From surgery to hospital discharge

  7. Hospital readmissions

    Number of hospital readmissions since discharge, assessed at each follow-up visit.

    Time frame: Month 3, Month 6, and Month 12

  8. Chronic postoperative pain

    Presence of chronic pain related to cardiac surgery.

    Time frame: Month 3, Month 6, and Month 12

  9. Analgesic consumption

    Type of analgesic medication and frequency of use since the previous follow-up assessment.

    Time frame: Month 3, Month 6, and Month 12

  10. Living situation

    Living at home versus institutionalization during follow-up.

    Time frame: Month 3, Month 6, and Month 12

  11. EQ-5D-5L visual analogue scale (EQ VAS)

    Self-rated health status assessed using the EQ-5D-5L visual analogue scale (0-100).

    Time frame: Baseline, Month 3, Month 6, and Month 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 36 months is above that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 30, 2026
StartActual
Dec 3, 2025
Primary completionEst.
Dec 3, 2028
CompletionEst.
Dec 3, 2028
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07677319
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Dec 3, 2025
Primary completion
Dec 3, 2028 (estimated)
Completion
Dec 3, 2028 (estimated)
Last update
Jun 30, 2026

Study contacts

Simon CARRE, MD
Contact
simon.carre@chu-bordeaux.fr
0556795679 ext. +33
Simon CARRE, MD
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion